Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Divina Glah"'
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0191953 (2018)
We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 mg and lixisenatide 20 μg (both added to basal insulin) in patients with type 2 diabetes (T2D) in Sweden.The Swedish Institute for Health Economics c
Externí odkaz:
https://doaj.org/article/c5a5bb8534e24bada06f77761d908fce
Publikováno v:
Drugs in Context, Pp 1-14 (2015)
Introduction: Management of type 2 diabetes mellitus (T2DM) often requires intervention with oral and injectable therapies. Across National Health Service (NHS) England, injectable therapies may be initiated in secondary, intermediate or primary care
Externí odkaz:
https://doaj.org/article/fb58e7ca699749b7a5041b93d8b24595
Publikováno v:
Diabetes Therapy
Introduction Type 2 diabetes represents a continuing healthcare challenge, and choosing cost-effective treatments is crucial to ensure that healthcare resources are used efficiently. The present analysis assessed the cost-effectiveness of once-weekly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f303c8b83004caa12f4817dc2be9baaa
https://doi.org/10.1007/s13300-020-00989-6
https://doi.org/10.1007/s13300-020-00989-6
Publikováno v:
Diabetes Therapy
Introduction Once-weekly semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue administered at a 1.0 or 0.5 mg dose. As head-to-head trials assessing once-weekly semaglutide as an add-on to 1–2 oral anti-diabetic drugs (OADs) vs other GLP-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed520d8c5a82f47fc7ba3ab69f5ea852
https://doi.org/10.1007/s13300-018-0424-2
https://doi.org/10.1007/s13300-018-0424-2
Publikováno v:
Diabetes Therapy
Introduction Once-weekly semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that is currently available as 1.0 mg and 0.5 mg dose for the treatment of type 2 diabetes (T2D). Currently, no head-to-head trial investigating once-weekly semaglutid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fca14a34f1c240415291106cb9e388fd
http://europepmc.org/articles/PMC5984931
http://europepmc.org/articles/PMC5984931
Publikováno v:
Diabetes Therapy
Introduction Insulin degludec/liraglutide (IDegLira) is the first basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a single pen injection device, and a once-daily treatment option for patients with type 2 diabetes mellitus (T2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83a133b832710df5c4e27a1c3896fb71
https://doi.org/10.1007/s13300-017-0266-3
https://doi.org/10.1007/s13300-017-0266-3
Publikováno v:
PharmacoEconomics. 34(9)
Once-daily insulin degludec/liraglutide (IDegLira) is the first basal insulin and glucagon like peptide-1 receptor agonist combined in one delivery device. Our aim was to investigate the cost effectiveness of IDegLira vs. basal insulin intensificatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e826e900068c2d51f82b5dc778e050e8
https://pubmed.ncbi.nlm.nih.gov/27438706
https://pubmed.ncbi.nlm.nih.gov/27438706
Publikováno v:
Primary care diabetes. 11(3)
Most diabetes care is done by general practitioners (GPs) in the UK. This study aimed to determine GPs' comfort level in initiating and intensifying injectable therapies, identifying any associated barriers, and assessing reasons for referral to spec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d2bfe99dc63d5975097a6f4ac2547ed
https://pubmed.ncbi.nlm.nih.gov/28395938
https://pubmed.ncbi.nlm.nih.gov/28395938
Publikováno v:
Drugs in Context
Drugs in Context, Pp 1-14 (2015)
Drugs in Context, Pp 1-14 (2015)
Introduction: Management of type 2 diabetes mellitus (T2DM) often requires intervention with oral and injectable therapies. Across National Health Service (NHS) England, injectable therapies may be initiated in secondary, intermediate or primary care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb4c06bb246fafcd4988baf1235ee5d7
https://pubmed.ncbi.nlm.nih.gov/25657811
https://pubmed.ncbi.nlm.nih.gov/25657811
Autor:
Divina, Glah, Steven, Tear
Publikováno v:
IDrugs : the investigational drugs journal. 11(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e80d9ddee0cbac856c0c6bf2cf097995
https://pubmed.ncbi.nlm.nih.gov/19024888
https://pubmed.ncbi.nlm.nih.gov/19024888